Tasdelen I - Search Results

1

Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.

Demiray M, Kurt E, Evrensel T, Kanat O, Arslan M, Saraydaroglu O, Ercan I, Gonullu G, Gokgoz S, Topal U, Tolunay S, Tasdelen I, Manavoglu O. Demiray M, et al. Among authors: tasdelen i. Cancer Invest. 2005;23(5):386-91. doi: 10.1081/cnv-67133. Cancer Invest. 2005. PMID: 16193637 Clinical Trial.

2

Acquired lymphangiectasis after breast conservation treatment for breast cancer: report of a case.

Tasdelen I, Gokgoz S, Paksoy E, Yerci O, Cetintas SK, Demiray M, Samsa V. Tasdelen I, et al. Dermatol Online J. 2004 Jul 15;10(1):9. Dermatol Online J. 2004. PMID: 15347491 Free article. Review.

3

BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.

Cecener G, Egeli U, Tunca B, Erturk E, Ak S, Gokgoz S, Tasdelen I, Tezcan G, Demirdogen E, Bayram N, Avci N, Evrensel T. Cecener G, et al. Among authors: tasdelen i. Cancer Invest. 2014 Oct;32(8):375-87. doi: 10.3109/07357907.2014.919302. Epub 2014 Jun 2. Cancer Invest. 2014. PMID: 24884828

4

Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.

Sevinc ED, Egeli U, Cecener G, Tezcan G, Tunca B, Gokgoz S, Tasdelen I, Tolunay S, Evrensel T. Sevinc ED, et al. Among authors: tasdelen i. Asian Pac J Cancer Prev. 2015;16(1):291-7. doi: 10.7314/apjcp.2015.16.1.291. Asian Pac J Cancer Prev. 2015. PMID: 25640367 Free article.

5

Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients.

Cecene G, Ak S, Eskiler GG, Demirdogen E, Erturk E, Gokgoz S, Polatkan V, Egeli U, Tunca B, Tezcan G, Topal U, Tolunay S, Tasdelen I. Cecene G, et al. Among authors: tasdelen i. Asian Pac J Cancer Prev. 2016;17(9):4241-4246. Asian Pac J Cancer Prev. 2016. PMID: 27797225 Free article.

6

Synchronous breast cancer in spouses.

Kahraman-Cetintaş S, Kurt M, Gökgöz S, Ozkan L, Engin K, Taşdelen I. Kahraman-Cetintaş S, et al. Among authors: tasdelen i. Tumori. 2006 May-Jun;92(3):244-5. doi: 10.1177/030089160609200311. Tumori. 2006. PMID: 16869244

7

Factors influencing axillary node metastasis in breast cancer.

Cetintaş SK, Kurt M, Ozkan L, Engin K, Gökgöz S, Taşdelen I. Cetintaş SK, et al. Among authors: tasdelen i. Tumori. 2006 Sep-Oct;92(5):416-22. doi: 10.1177/030089160609200509. Tumori. 2006. PMID: 17168435

8

CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer.

Tunca B, Egeli U, Cecener G, Tezcan G, Gökgöz S, Tasdelen I, Bayram N, Tolunay S, Umut G, Demirdogen E, Erturk E, Ak S, Cetintas S, Evrensel T. Tunca B, et al. Among authors: tasdelen i. Tumori. 2012 Mar-Apr;98(2):243-51. doi: 10.1177/030089161209800211. Tumori. 2012. PMID: 22677992

9

Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.

Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz S, Tolunay S, Tasdelen I. Erturk E, et al. Among authors: tasdelen i. Mol Cell Biochem. 2014 Oct;395(1-2):77-88. doi: 10.1007/s11010-014-2113-4. Epub 2014 Jun 19. Mol Cell Biochem. 2014. PMID: 24942235

10

Expression and clinical significance of miRNAs that may be associated with the FHIT gene in breast cancer.

Sevinc ED, Cecener G, Ak S, Tunca B, Egeli U, Gokgoz S, Tolunay S, Tasdelen I. Sevinc ED, et al. Among authors: tasdelen i. Gene. 2016 Sep 30;590(2):278-84. doi: 10.1016/j.gene.2016.05.033. Epub 2016 May 25. Gene. 2016. PMID: 27236032

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

50 results

Search Page

Filters